Kyongbo Pharmaceutical Co Ltd (214390) — Cash Flow Quality Index
Kyongbo Pharmaceutical Co Ltd (214390) has a Cash Flow Quality Index of -0.19x as of June 2026. Operating cash flow of ₩-565.17 Million is below net income of ₩2.97 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore 214390 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Kyongbo Pharmaceutical Co Ltd Cash Flow Quality Index (2014–2025)
Historical Cash Flow Quality Index for Kyongbo Pharmaceutical Co Ltd across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 214390 cash flow conversion.
Annual Cash Flow Quality Index for Kyongbo Pharmaceutical Co Ltd (2014–2025)
Year-by-year earnings quality comparison for Kyongbo Pharmaceutical Co Ltd.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 40.90x | ₩7.46 Billion | ₩182.29 Million | ▲ +127144.6% |
| 2024 | 0.03x | ₩149.12 Million | ₩4.64 Billion | ▼ -98.0% |
| 2023 | 1.63x | ₩4.84 Billion | ₩2.97 Billion | ▼ -90.2% |
| 2022 | 16.59x | ₩10.13 Billion | ₩610.59 Million | ▲ +650.0% |
| 2020 | 2.21x | ₩20.80 Billion | ₩9.40 Billion | ▼ -50.6% |
| 2019 | 4.48x | ₩23.67 Billion | ₩5.29 Billion | ▲ +5260.6% |
| 2018 | -0.09x | ₩-1.14 Billion | ₩13.12 Billion | ▼ -106.0% |
| 2017 | 1.44x | ₩25.81 Billion | ₩17.96 Billion | ▼ -27.9% |
| 2016 | 1.99x | ₩25.33 Billion | ₩12.71 Billion | ▲ +1127.5% |
| 2015 | 0.16x | ₩4.24 Billion | ₩26.11 Billion | ▼ -91.3% |
| 2014 | 1.86x | ₩16.04 Billion | ₩8.64 Billion | — |